The Effects of Bromocriptine on Preventing Postpartum Flare in Systemic Lupus Erythematosus Patients from South China
نویسندگان
چکیده
OBJECTIVE Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the postpartum disease relapse. METHODS Patients were randomly divided into the treatment group (bromocriptine, 2.5 mg oral, twice a day for 14 days after delivery) and the control group. All the patients were followed up for 12 months. Clinical features were recorded every 4 weeks. Serum prolactin and estradiol levels were measured at the second week and the second month after delivery. The endpoint of the study was disease relapse and defined when SLEDAI score increased by ≥3 points from the antenatal baseline. RESULTS (1) Serum levels of prolactin and estradiol decreased significantly in bromocriptine treatment group at the second week (P < 0.001) and second month (P < 0.05) after delivery compared to control group. (2) The relapse rate of the treatment group was lower than the control group (χ (2) = 4.68, P = 0.0305). CONCLUSIONS Two weeks of oral bromocriptine treatment in postpartum SLE patients may relieve the disease from hyperprolactinemia and hyperestrogenemia and may be beneficial in preventing the patients from disease relapse.
منابع مشابه
Three cases of systemic lupus erythematosus and review of the mechanisms concerning treatment with intravenous immunoglobulins (IVIG).
The systemic lupus erythematosus (SLE) is an autoimmune disorder with a broad array of clinical signs. In this research, we aimed to use intravenous immunoglobulins (IVIG) called intacglobin as monotherapy to manage an SLE in three patients. Laboratory investigations for SLE diagnosis were done, including the detection of anti-nuclear antibodies (ANA) and SLE confirmation by detecting high tite...
متن کاملCodon 72 Polymorphism of p53 Gene and Hematologic Manifestations in Patients with Systemic Lupus Erythematosus
Background: Systemic lupus erythematosus is a systemic autoimmune disorder with unclear etiology. The importance of some genes in the development of systemic lupus erythematosus has been implicated. The gene polymorphism in codon 72 has attracted a lot of attention and its role in the occurrence or progression of many cancers and autoimmune diseases especially systemic lupus erythematosus has ...
متن کاملIL-17 is Aberrantly Overexpressed Among Under-treatment Systemic Lupus Erythematosus Patients
Background & Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic inflammatory immune response. Current therapies mostly rely on glucocorticoids which are accompanied by side-effects and mostly fail to achieve a favorable remission. Th17 subpopulation of T cells is increased in exacerbated SLE as IL-17 cytokine is overexpressed. ...
متن کاملCutaneous manifestations of systemic Lupus Erythematosus: A study from Ahwaz
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease in which cutaneous lesions occur in 72%-85% of patients. Objective: This study was conducted to determine the pattern and incidence of skin lesions in SLE patients in Ahwaz. Patients and Methods: Thirty patients with SLE fulfilling the clinical and laboratory criteria of the American Rheumatism Association who were admitted...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2015 شماره
صفحات -
تاریخ انتشار 2015